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ABSTRACT:
Metabolic disposition of 5,5-dimethyl-2-(1-methylethylidene)-cyclo-
hexanone (I) was examined in rats. Compound (I) was administered
orally (250 mg/kg of body weight/day) to rats for 5 days. The following
urinary metabolites were isolated and identified: 4,5,6,7-tetrahydro-
3,6,6-trimethylbenzofuran (III), 3,3-dimethylcyclohexanone (VI), 5,5-di-
methyl-3-hydroxy-2-(1-methylethylidene)-cyclohexanone (X), 5,5-di-
methyl-2-(1-hydroxymethylethyl)-cyclohexanone (IX), 3-hydroxy-5-
hydroxymethyl-5-methyl-2-(1-methylethylidene)-cyclohexanone (XI),
5,6-dihydro-3,6,6-trimethyl-2(4H)-benzofuranone (VIII), and 5,5-di-
methyl-3-hydroxy-2-(1-carboxy ethylidene)-cyclohexanone (XIII). In-
cubation of compound (I) with phenobarbital (PB)-induced rat liver
microsomes in the presence of NADPH resulted in the formation of a
metabolite, tentatively identified as a furanoterpene (III) based on
proton magnetic resonance, gas chromatography, and gas chroma-
tography-mass spectroscopy analyses. The formation of III was in-
hibited to a significant extent by carbon monoxide, metyrapone, SKF
525-A, and cytochrome c, suggesting the participation of PB-induced
microsomal cytochrome P-450 system in the conversion of I to III.
Compound I gave type I spectral change in the PB-induced liver
microsomes and the dissociation constant (Ks) for I was 38.5 mM.
Intraperitoneal administration of a single dose (250 mg/kg) of I to rats
resulted in 26, 23, and 41% decreases in the levels of cytochrome
P-450, glucose-6-phosphatase, and aminopyrine N-demethylase, re-
spectively, at the end of 24 h. During this period, a 11-fold increase in
serum glutamate pyruvate transaminase level was also observed.
However, a decrease in the level of cytochrome P-450 and glucose-
6-phosphatase, and an increase in serum glutamate pyruvate
transaminase values were comparatively more pronounced when
R-(1)-pulegone (250 mg/kg) or CCl4 (0.6 ml/kg) was administered to
rats. Pretreatment of rats with PB potentiated the hepatotoxicity
caused by I, whereas pretreatment with 3-methylcholanthrene pro-
tected from it. This suggests that PB-induced cytochrome P-450-
catalyzed reactive metabolites may be responsible for the toxic ef-
fects caused by I.
R-(1)-pulegone, a naturally occurring monoterpene ketone, is a
potent hepatotoxin and the bioactivation of this compound to reactive
metabolites is mostly responsible for the observed toxicity (Gordon et
al., 1982, 1987; Thorup et al., 1983; Madyastha and Moorthy, 1989;
McClanahan et al., 1989; Moorthy et al., 1989a,b, 1991; Madyastha
and Raj, 1990, 1992). The hepatotoxin gets metabolized following
two major pathways (Madyastha and Raj, 1993). One of the major
pathways is initiated through the regiospecific hydroxylation of
R-(1)-pulegone to 9-hydroxypulegone, which on intramolecular cy-
clization followed by dehydration yields a furanoterpene, menthofu-
ran (Gordon et al., 1987; McClanahan et al., 1989; Madyastha and
Raj, 1990, 1993). The second major pathway is involved in the
stereoselective hydroxylation of R-(1)-pulegone at C-5 position to
form 5-hydroxypulegone which gets transformed to piperitenone
(Madyastha and Raj, 1993). In fact, most of the metabolites of
R-(1)-pulegone are derived from menthofuran and piperitenone
(Madyastha and Raj, 1992; Madyastha and Gaikwad, 1999). Mentho-
furan, the proximate toxin, accounts for nearly half the toxicity
mediated by R-(1)-pulegone (Thomassen et al., 1988, 1990), suggest-
ing that the remaining 50% of toxicity is caused by metabolites
derived independently of menthofuran. It appears that the metabolites
derived from piperitenone could also contribute to R-(1)-pulegone-
mediated toxicity because its biotransformation yields p-cresol and
6,7-dehydromenthofuran besides other metabolites (Madyastha and
Gaikwad, 1999). p-Cresol is known to cause toxicity in both liver and
lung (Deichmann and Keplinger, 1958; Thompson et al., 1994). The
6,7-dehydromenthofuran could also contribute to toxicity by virtue of
its being a furanoterpene (Boyd, 1982). This suggests that the stereo-
selective hydroxylation at the C-5 position is one of the key steps
involved in the bioactivation of R-(1)-pulegone to reactive metabo-
lites responsible for toxicity. The available evidences suggest that
both the major pathways (5-hydroxylation and 9-hydroxylation path-
ways) involved in the metabolism of R-(1)-pulegone yield reactive
metabolites that can generate toxic effects. However, the contribution
of the individual pathways toward R-(1)-pulegone-mediated toxicity
has not been assessed (Scheme 1).
The characteristic structural features of R-(1)-pulegone are the
presence of an a-isopropylidene ketone unit and a chiral center at C-5.
Both these structural features appear to be necessary for the com-
pound to elicit maximum toxicity (Gordon et al., 1982). In fact, the
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C-5 methyl group should have a proper orientation as in R-(1)-
pulegone. It is known that inversion of configuration of the C-5
methyl group in R-(1)-pulegone markedly affects the hepatotoxic
potential. Thus, S-(2)-pulegone is approximately one-third as hepa-
totoxic as its enantiomer, R-(1)-pulegone (Gordon et al., 1982). It
would be interesting to assess the hepatotoxic potential of a compound
that is structurally similar to R-(1)-pulegone but without a chiral
center at the C-5 position. One can envisage such a situation if the C-5
hydrogen in R-(1)-pulegone is replaced by another methyl group as in
5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone (I), a compound
structurally similar to R-(1)-pulegone. In this compound (I) the
metabolic pathway initiated by C-5 hydroxylation is blocked due to an
additional methyl substitution at the C-5 position. It would be inter-
esting to find out whether compound I gets metabolized following a
pathway initiated through regiospecific hydroxylation of the methyl
group that is syn to the carbonyl group (C-10 methyl) or whether the
compound I is not accepted by the hydroxylase system as a substrate.
If C-10 hydroxylated product is formed from compound I, would such
a compound undergo spontaneous intramolecular cyclization to a
hemiketal, which upon dehydration yields a furanoterpene in a manner
analogous to the formation of menthofuran from R-(1)-pulegone
(Gordon et al., 1987; Moorthy et al., 1989a; Madyastha and Raj,
1990). To understand the role of chiral center at C-5 in R-(1)-
pulegone-mediated toxicity, metabolic studies with 5,5-dimethyl-2-
(1-methylethylidene)-cyclohexanone (compound I) were undertaken
both in vivo and in vitro. This study describes the isolation and
characterization of several novel metabolites from the urine of rats
dosed with compound I. Some of the metabolites isolated and char-
acterized are hitherto not known. The effects of compound I on
hepatic microsomal enzymes in vivo are also reported.
Materials and Methods
Chemicals. 3-Methylcholanthrene (3-MC)1, glucose 6-phosphate, glucose
6-phosphate dehydrogenase, NADP1, methylcellulose, and Tris-HCl were
supplied by Sigma Chemical Co. (St. Louis, MO). Phenobarbital (PB) was a
generous gift from IDPL (Hyderabad, India).
Synthetic Methods. Piperitenone was synthesized as reported earlier (Na-
kanishi et al., 1980). 5,5-Dimethyl-2-(1-methylethylidene)-cyclohexanone (I)
was synthesized as follows: Methyl magnesium iodide (in 60 ml of ether)
prepared from dry magnesium turning (3.4 g) and methyl iodide (19.88 g) were
taken in a round bottomed flask (250 ml) equipped with a sealed stirrer, a
pressure equalizing funnel, and a reflux condenser. The contents of the flask
were cooled to 227°C, 13.84 g of dried copper (I) chloride was added, and the
mixture was stirred for 30 to 45 min at 227°C. Then with rapid stirring, a
solution of piperitenone (15.0 g) in ether (75 ml) was added drop-wise. After
the addition of piperitenone, stirring was continued for another period of 1 h
at 227°C and overnight at room temperature. The reaction complex was
decomposed by adding 50 ml of cold saturated ammonium chloride solution
with continued stirring and cooling, followed by 20 ml of 1 N hydrochloric
acid to give a clear solution. The ethereal layer was separated and the aqueous
phase was extracted with ether (100 ml 3 2). The combined ether extract was
dried over anhydrous sodium sulfate, and evaporated to a colorless liquid (90%
yield). The compound was purified by column chromatography over neutral
alumina using hexane as eluent. The purity of 5,5-dimethyl-2-(1-methyleth-
ylidene)-cyclohexanone used in this study was more than 99% on the basis of
gas chromatography (GC) analysis. The compound has the following spectral
characteristics. Relative front (Rf) 0.45 (system I), retention time (Rt) 13.1 min.
Infrared (IR) spectrum (neat) showed absorptions at 1670 and 1610 cm21
(conjugated carbonyl group). Proton magnetic resonance (PMR) spectra
(CDCl3) were: d 2.5 (t, 2H, J 5 6.6 Hz, C-3 methylene protons), 2.28 (s, 2H,
C-6 methylene protons), 1.99 (s, 3H, C-10 methyl protons), 1.72 (s, 3H, C-11
methyl protons), 1.52 (t, 2H, J 5 6.8 Hz, C-4 protons), and 0.98 (s, 6H, C-7
and C-8 methyl protons). Mass spectra were: m/z 166 (M1), 151 (M1-CH3),
123 (M1-C2H3O), and 110 (M1-C3H4O). Compound I was converted to
compound III following the procedure reported earlier (Bedoukian, 1948).
Animals and Dosing. Adult male rats (Wistar strain, 180–200 g) were used
in these studies. For isolation of metabolites, 5,5-dimethyl-2-(1-methylethyli-
dene)-cyclohexanone (I, 250 mg/kg of b.wt./day) was administered to rats (n 5
20) once daily for 5 days by gastric intubation as a suspension in 1 ml of 1%
methylcellulose solution. Control rats (n 5 6) received only the vehicle.
Control and experimental rats were housed separately in stainless steel me-
tabolism cages with free access to food and water (laboratory animal food from
Brooke Bond and Lipton, Bangalore, India). Urine was collected daily in
bottles maintained at 0–4°C.
To evaluate the hepatotoxic potential of compound I and compare these
values to R-(1)-pulegone or CCl4-mediated toxicity, rats were treated with
5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone (I, 250 mg/kg of b.wt.),
R-(1)-pulegone (250 mg/kg of b.wt.), or CCl4 (0.6 ml/kg of b.wt.) as a
suspension in 0.3 ml of coconut oil. Control rats received only vehicle.
Treatments were carried out i.p. Both control and experimental rats were
housed separately in cages with free access to food and water. Animals were
sacrificed by cervical dislocation 24 h after administration of test compounds.
In pretreatment experiments, rats were pretreated with PB (in 0.3 ml of 0.9%
NaCl solution, 80 mg/kg of b.wt./day) or 3-MC (suspended in 0.3 ml of
coconut oil, 40 mg/kg of b.wt./day) for 4 days before i.p. administration of
compound I (250 mg/kg of b.wt.). However, at this dosage more than 50% of
the PB-treated rats died within 24 h of treatment. PB and 3-MC were admin-
istered i.p. For serum glutamate pyruvate transaminase (SGPT) determinations,
rats were sacrificed while under light anesthesia and blood was drawn from the
heart by cardiac puncture.
PB-induced microsomes were prepared from livers of rats treated with PB
(80 mg/kg of b.wt./day) for 4 days. The rats were sacrificed by cervical
dislocation 24 h after the final dose and the livers were perfused with ice-cold
0.15 M KCl solution.
Extraction of Urinary Metabolites. The urine samples collected daily
from control and experimental rats were adjusted to pH 4 to 5 with 1 N HCl
and extracted separately with diethyl ether. Each day, ether extracts were
pooled and stored at 0–4°C. The pooled ether extract was concentrated and
extracted with 5% (w/v) aqueous NaHCO3 to separate acidic and neutral
metabolites. The bicarbonate phase acidified and extracted with ether to get the
total acidic fraction. The ether extract, after removal of acidic metabolites,
contained neutral metabolites.
Preparation of Microsomes. The livers were minced and homogenized in
Tris-HCl buffer (0.05 M, pH 7.4) containing 0.25 M sucrose, and the micro-
somes were prepared as reported earlier (Lu and Levin, 1972). Microsomal
pellets were suspended in Tris-HCl buffer (0.05 M, pH 7.8) containing 0.25 M
sucrose and 20% glycerol (v/v) and were stored at 220°C. Protein was
estimated by the method of Lowry et al. (1951).
Enzyme Assays. Cytochrome P-450 (Omura and Sato, 1964), SGPT (Re-
itman and Frankel, 1957), glucose-6-phosphatase (Traiger and Plaa, 1971), and
aminopyrine N-demethylase (Werringloer, 1978) were determined according
to the published methods.
Transformation In Vitro. Microsomal protein (2 mg/ml) was incubated in
the presence of 0.5 mM NADP1, 5.0 mM glucose 6-phosphate, 1 U of glucose
6-phosphate dehydrogenase, 10 mM of MgCl2, compound I (2 mM, in 50 ml
1 Abbreviations used are: 3-MC, 3-methylcholanthrene; GC, gas chromatog-
raphy; IR, infrared; MS, mass spectroscopy; PMR, proton magnetic resonance;
Rf, relative front; Rt, retention time; TLC, thin layer chromatography; PB, pheno-
barbital; SGPT, serum glutamate pyruvate transaminase; HRMS, high resolution
mass spectral.
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of acetone), and 0.01 M Tris-HCl (pH 7.4) in a total volume of 5.0 ml. The
reaction was initiated by the addition of NADPH-generating system, and
incubated aerobically in a rotary shaker for 30 min at 37°C. At the end of the
incubation period, the assay mixtures were cooled to 0–4°C, the protein was
precipitated by adding 2.0 ml each of saturated Ba(OH)2 and 0.25 M ZnSO4
solution, and the mixture centrifuged (3000g). The supernatant was extracted
with methylene chloride (20 ml 3 3), concentrated, and an aliquot was
subjected to GC and GC-mass spectroscopy (MS) analyses.
Effect of inhibitors on the transformation in vitro by PB-induced rat liver
microsomes was determined as follows. Each inhibitor was preincubated with
the microsomes at 37°C for 5 min, and then the assay was carried out as
described above. Metyrapone, SKF 525-A, and piperonyl butoxide were added
as a solution in 50 ml of acetone, and cytochrome c in 100 ml of distilled water.
The concentration of each inhibitor used is as mentioned in Table 1. In control
assays only respective solvents were added and incubated at 37°C for 5 min
before the assays were carried out. Carbon monoxide inhibition experiments
were carried out by bubbling CO into the assay mixture for 1 to 2 min before
the addition of compound I and NADPH-generating system. Similarly, N2 was
bubbled through the control assay mixture for 1 to 2 min.
Binding Studies. Binding studies were carried out in 50 mM potassium
phosphate buffer (pH 7.4) with control and PB-induced rat liver microsomes
(;3 mg/ml). Compound I (5–50 mM) dissolved in 1 to 10 ml of acetone was
added to the sample cuvette and the same amount of acetone was added to the
reference cuvette. The difference spectrum was recorded between 350 and 500
nm. A family of curves was obtained by adding increasing amounts of the
compound I to the sample cuvette. Addition was continued until no additional
increase in absorption occurred. The volume of acetone added was less than
1% of the final suspension. The extent of binding was measured by the
difference in absorbance between the wavelengths of maximum and minimum
absorption (DAmax). The dissociation constant (Ks) was determined by plotting
reciprocal DAmax versus reciprocal substrate concentration.
Chromatographic Procedures. Thin layer chromatography (TLC) was
carried out on silica gel-G coated plates (0.25 mm for analytical, 0.75 mm for
preparative TLC) developed with either hexane/ethyl acetate (system I, 90:10,
v/v; system II, 75:25, v/v) or hexane/ethyl acetate/acetic acid (system III,
79:20:1, v/v) as the solvent systems. The compounds were visualized by
spraying with 3% vanillin in 1% methanolic sulfuric acid followed by heating
at 100°C for 5 to 10 min.
GC analyses were carried out on a Shimadzu model 14A instrument
equipped with a hydrogen flame ionization detector and Shimadzu HR-1 wide
bore capillary column (15-m 3 0.5-mm diameter). Nitrogen was used as the
carrier gas at a flow rate of 30 ml/min. Initially, the column temperature was
maintained at 60°C for 10 min, after which it was raised by 5°C/min to 150°C
and maintained at 150°C for 5 min.
Spectra. IR spectra were recorded on a Perkin-Elmer model 781 spectro-
photometer. Proton and 13C NMR spectra were recorded on a JEOL FT-300
MHz spectrometer. Chemical shifts are reported in ppm, with respect to
tetramethylsilane as the internal standard. MS analyses were performed on a
JEOL-JMX-DX 303 instrument attached to a JMA-DA-5000 data system.
GC-MS analyses were performed on a Shimadzu QP-2000 instrument. A
capillary column ULBON HR-1 (50 m 3 0.25 mm in diameter) was used for
separation of metabolites. The column temperature was programmed from
100–250°C. The initial temperature was 100°C for 6 min and then heated at
the rate of 10°C/min to 250°C. Helium was used as a carrier gas at a flow rate
of 2 ml/min. High resolution mass spectral analyses (HRMS) were carried out
using a VG Auto spec M mass spectrometer. Perfluorokerosene was used as
internal reference and the data was acquired at 5000 resolution.
Results
Biotransformation of 5,5-Dimethyl-2-(1-methylethylidene)-cy-
clohexanone(I) In Vivo. The composition of the total urine extract
TABLE 2
GC analysis of the total urine extract
Analysis was carried out as described in the text. Roman numbers represent the different
metabolites. Metabolites VIII and XIII do not separate under the GC conditions used. The
structure of the metabolites, their retention time, and percentage of composition are presented.
Purified metabolites VIII and XIII have retention times of 28.1 and 28.0 min, respectively.
Compound Rt
Percentage of
Composition of
Total Urine
Extract
min
I 13.1 20.2
III 7.7 5.3
VI 1.7 2.4
IX 22.2 5.7
X 21.5 6.4
XI 23.8 5.4
VIII
28.0 47.1
XIII
Benzoic acid (Endogenous compound) 2
Unidentified (minor) metabolites 5.5
TABLE 1
Effect of various inhibitors on the transformation of I to III by PB-induced rat
liver microsomes
Inhibitor Concentration Percentage of Inhibition
Control —— 0.0
CO Bubbled for 2 min 81*
Metyrapone 1 mM 74
Piperinyl butoxide 2 mM 57
SKF 525-A 0.2 mM 77
Cyt. C 5 mM 86
* No inhibition was observed when the assay mixture was bubbled with N2 for 1 to 2 min
before the addition of compound I and NADPH.
100% activity (0.0% inhibition) represents 40 nmol of furan formed mg21 h21. The assays
were carried out as described in the text.
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(Table 2) was determined by GC analyses. The analyses showed the
presence of eight peaks corresponding to metabolites III, VI, VIII, IX,
X, XI, XIII, and unmetabolized compound I (Fig. 1). The peaks
corresponding to these metabolites were enhanced when mixed with
the purified metabolites isolated by column chromatography. GC
profile also showed a couple of very minor peaks, which accounted
for 5.5% of the total metabolites formed. Nearly 45% of the admin-
istered dose was excreted in the urine as metabolites and unmetabo-
lized substrate. However, it should be noted here that both substrate
and its metabolites are volatile and a considerable amount must have
been lost during extraction. Unmetabolized compound I was nearly
20% of the total urine extract. Metabolites VIII and XIII could not be
separated under the GC conditions used.
TLC analysis (system I) of neutral fraction (0.9 g) showed the
presence of at least seven compounds that were absent in control urine
extract. The metabolites present in this fraction were separated by
column chromatography over neutral alumina (50 g), and the column
was initially eluted with pentane followed by hexane/ethyl acetate
FIG. 1. Probable metabolic pathways of 5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone (I).
A and B represent a major and a minor pathway, respectively.
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mixtures. Elution of the column with pentane yielded a fraction
containing mainly one compound (Rf 0.76, system I; Rt 7.7 min). This
compound had the following spectral characteristics. IR spectrum
(neat) showed absorptions around 1630 and 1460 cm21 (characteristic
of furan ring). PMR spectra (CDCl3, Fig. 2) were: d 7.0 (s, 1H, C-2
aromatic proton), 2.3 to 2.25 (m, 4H, C-4 and C-7 methylene protons),
1.9 (s, 3H, C-10 methyl protons), 1.5 (t, 2H, J 5 3Hz, C-5 methylene
protons), 0.99 (s, 6H, C-8 and C-9 methyl protons). MS (Fig. 2, inset)
were: m/z 164 (M1), 149 (M1-CH3), 121 [M1-(CO1CH3)], and 108
(M1-C4H8, base peak). The base peak at m/z 108 is characteristic of
the furanoid fragment (Pinder, 1977). Based on the spectral charac-
teristics, the metabolite was identified as 4,5,6,7-tetrahydro-3,6,6-
trimethyl benzofuran (III, Fig. 1). The structure assigned was also
confirmed by synthesizing this compound following the reported
procedure (Bedoukian, 1948) and comparing the PMR and mass
spectrum of the synthetic compound with that of the isolated metab-
olite (III, Fig. 2).
Elution of the column with hexane gave a fraction containing
unmetabolized compound I (Rf 0.45, system I; Rt 13.1 min). This was
also confirmed by comparing its mass spectra with that of authentic
compound I.
Additional elution of the column with hexane/ethyl acetate (9.5:0.5,
v/v) yielded fractions containing mainly one compound (Rf 0.35,
system I; Rt 1.77 min) that was purified by preparative TLC (system
I). This compound had the following spectral characteristics. IR
spectrum (neat) showed absorptions at 1720 cm21 (carbonyl group).
PMR spectra (CDCl3) were: d 2.24 (t, 2H, J 5 6.6Hz, C-6 protons),
2.12 (s, 2H, C-2 protons), 1.85 (q, 2H, C-5 protons), 1.55 (t, 2H, J 5
5.7Hz, C-4 protons), and 0.95 (s, 6H, C-7 and C-8 methyl protons).
MS spectra were: m/z 126 (M1), 111 (M1-CH3), 83 (M1-C2H3O,
base peak), and 69 (M1-C3H5O). From the spectral data, the metab-
olite was identified as 3,3-dimethyl cyclohexanone (VI, Fig. 1). The
structure assigned was also confirmed by synthesizing this metabolite
(VI) following the reported procedure (House and Wilkins, 1976) and
then comparing its spectral data with those of the metabolite isolated
(VI).
The metabolite with Rf 0.52 (system II) and Rt 21.5 min was eluted
from the column with hexane/ethyl acetate (24:1, v/v). It was also
purified by preparative TLC (system II), and the purified metabolite
had the following spectral characteristics. IR spectrum (neat) showed
absorptions around 3445 cm21 (hydroxyl group), 1677, and 1620
cm21 (conjugated carbonyl group). PMR spectra (CDCl3, Fig. 3)
were: d 3.6 (2 d, 1H, J 5 4.8Hz, C-3 proton), 2.35 (d, 2H, J 5 15.6Hz,
C-6 protons), 2.15 (d, 2H, J 5 19.2Hz, C-4 protons), 1.95 (s, 3H, C-10
methyl protons), 1.75 (s, 3H, C-11 methyl protons), and 0.95 and 0.92
(2s, 6H, C-7 and C-8 methyl protons). Mass spectra (Fig. 3, inset)
were: m/z 182 (M1), 164 (M1-H2O), 149 (M1-H2O-CH3), 121 (M1-
CO-H2O- CH3), and 83 (M1-C6H11O). HRMS found M1, 182.1304;
C11H18O2 requires 182.1306. From the spectral data, the metabolite
was identified as 5,5-dimethyl-3-hydroxy-2-(1-methylethylidene)-
cyclohexanone (X, Fig. 1).
Elution of the column with hexane/ethyl acetate (47:3, v/v) gave a
fraction containing mostly one compound (Rf 0.48, system II; Rt 22.2
min), which was additionally purified by preparative TLC (system II).
This compound had the following spectral characteristics. IR spec-
trum (neat) indicated the presence of a hydroxyl (3450 cm21) and
carbonyl (1706 cm21) groups. PMR spectrum (CDCl3, Fig. 4) were:
d 3.3 (d, 2H, J 5 3.3 Hz, C-10 hydroxy methyl protons), 2.3 to 1.5 (m,
8H, ring methylene protons), 0.85 (d, 3H, J 5 7.8 Hz, C-11 methyl
protons), and 0.81 (s, 6H, C-7 and C-8 methyl protons). Mass spectra
(Fig. 4, inset) were: m/z 184 (M1), 169 (M1-CH3), 153 (M1-CH3-
H2O), 142 (M1-C3H6), 111 (M1-C5H13), and 69 (base peak). HRMS:
C11H20O2 requires 184.1463, found M1, 184.1470. Based on these
FIG. 2. PMR spectra and electron impact mass spectra (inset) of 4,5,6,7-tetrahydro-3,6,6-trimethyl benzofuran (III).
837METABOLISM AND TOXICITY OF C-5 SUBSTITUTED PULEGONE IN RATS
spectral characteristics the metabolite was identified as 5,5-dimethyl-
2-(1-hydroxymethylethyl)-cyclohexanone (IX, Fig. 1).
One of the neutral metabolites with Rf 0.4 (system II) and Rt 23.83
min was eluted with 9:1 hexane/ethyl acetate and had the following
spectral characteristics. IR spectrum (neat) indicated the presence of
hydroxyl group (3440 cm21) and conjugated carbonyl group (1668
and 1620 cm21). PMR spectra (CDCl3, Fig. 5) were: d 3.33 (m, 3H,
hydroxy methyl attached to C-5 and C-3 methylene protons), 2.34 (2s,
2H, C-6 methylene protons), 2.17d and 2.07 (2 d, 2H, J 5 1.5 Hz, C-4
protons), 1.96 (s, 3H, C-10 methyl protons), 1.73 (s, 3H, C-11 methyl
protons), and 0.93 (s, 3H, methyl protons at C-5). Mass spectra (Fig.
5, inset) were: m/z 198 (M1), 182 (M1-O), 162 (M1-2H2O), 151
(M1-CH3O2), 135 (M1-C2H7O2), 121 (M1-C3H9O2), 109 (M1-
C4H9O2), and 69 (base peak). HRMS: found (M1-16), 182.1301;
C11H18O2 requires 182.1306. The mass spectra of metabolite XI (Fig.
5, inset) showed that the abundance of molecular ion (M1) was
extremely low hence (M1-O) ion was considered for HRMS analysis.
Based on these spectral characteristics, the compound was assigned
the structure 3-hydroxy-5-hydroxymethyl-5-methyl-2-(1-methyleth-
ylidene)-cyclohexanone (XI, Fig. 1).
Additional elution of the column with 17:3 hexane/ethyl acetate
gave a fraction, which upon TLC analysis (system II) showed the
presence of a compound (Rf 0.38, system II; Rt 28.0 min) along with
some minor impurities. The compound (Rf 0.38) was additionally
purified by preparative TLC (system II) and it had the following
spectral characteristics. IR spectrum (neat) indicated the presence of a
conjugated carbonyl group (1682 and 1620 cm21). PMR spectrum
(CDCl3, Fig. 6) were: d 5.34 (s, 1H, C-7 olefinic proton), 2.5 (t, 2H,
J 5 6.6 Hz, C-4 protons), 1.78 (s, 3H, C-10 methyl protons), 1.64 (t,
2H, J 5 7.2 Hz, C-5 protons), and 1.09 (s, 6H, C-8 and C-9 methyl
protons). 13C NMR spectrum (75 MHz, CDCl3, Fig. 7) were: d 188.5
(C2), 140.9 (C7a), 135.4 (C3a), 124.3 (C3), 119.3 (C7), 37.2 (C4), 32.6
(C6), 28.9 (C9 and C10), 19.6 (C5), and 8.2 (C8). Mass spectra (Fig. 6,
inset) were: m/z 178 (M1), 162 (M1-O), 147 (M1-CH3O), 134
(M1-CO2), and 107 (M1-C3H3O2). Based on all these spectral char-
acteristics, the metabolite was identified as 5,6-dihydro-3,6,6-
trimethyl-2(4H)-benzofuranone (VIII, Fig. 1).
Acidic Metabolites. Examination of the acidic fraction by TLC
(system III) showed one compound (Rf 0.49 system III) that is not
present in control urine extract. The fraction (0.8 g) was chromato-
graphed on a silica gel column (40 g), and the metabolite corresponding
to compound Rf 0.49 (system III) was eluted with 19:1 hexane/ethyl
acetate. The metabolite had the following spectral characteristics. IR
spectrum (neat) showed broad absorption around 3464 cm21 (acid hy-
droxyl group) and at 1706 and 1630 cm21 (conjugated carbonyl group).
PMR spectrum (CDCl3 Fig. 8) were: d 6.95 (s, 1H, acidic proton), 3.45
(t, H, J 5 5.7 Hz, C-5 proton), 2.19 (s, 3H, C-11 methyl protons), 1.6 to
2.7 (m, 4H. ring methylene protons), and 1.14 and 1.08 (2s, 6H, C-7 and
C-8 methyl protons). Mass spectra (Fig. 8, inset) were: m/z 212 (M1),
196 (M1-O), 178 (M1-H2O2), 151 (M1-CO3H), and 136 (M1-C2H4O3).
Based on the spectral characteristics, the compound was tentatively
identified as 5,5-dimethyl-3-hydroxy-2-(1-carboxyethylidene)-cyclohex-
anone (XIII, Fig. 1).
Transformation of Compound I by PB-Induced Rat Liver Mi-
crosomes. PB-induced rat liver microsomes were incubated aerobi-
cally with compound I in the presence of NADPH as described under
Materials and Methods. The methylene chloride extract of the assay
mixture on TLC (system I) and GC analyses indicated the presence of
only one metabolite (Rf 0.76, system I; Rt 7.7 min), which corre-
sponded to that of 4,5,6,7-tetrahydro-3,6,6-trimethyl benzofuran (III,
FIG. 3. PMR spectra and electron impact mass spectra (inset) of 5,5-dimethyl-3-hydroxy-2-(1-methylethylidene)-cyclohexanone (X).
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Fig. 1). The identity of the metabolite formed (III) was also confirmed
by comparing its mass spectral analysis with that of compound III
isolated from the urine extract and compound III prepared following
the reported procedure (Bedoukian, 1948) [m/z 164 (M1), 149 (M1-
CH3), 121 (M1-CO-CH3), and 108 (M1-C4H8, base peak, character-
istic of a furan ring)]. The rate of compound III formed was shown to
be 40 nmol mg21 h21. NADH could not support the enzymatic
conversion of compound I to III. The transformation of compound I to
compound III was significantly greater (40 nmol mg21h21) in micro-
somes obtained from PB-pretreated rats than in control microsomes
(20.2 nmol mg21h21). However, the formation of compound III was
not observed when 3-MC-treated microsomes were used. The trans-
formation of I to III is initiated by the regiospecific hydroxylation
(C-10 hydroxylation) of I to its 10-hydroxy compound, which is
highly unstable and so spontaneously undergoes cyclization followed
by dehydration to a furanoterpene (III, Fig. 1).
Inhibitor Studies. Table 1 shows the effect of various inhibitors on
the transformation of I to III (C-10 hydroxylation) by PB-pretreated
rat liver microsomes. Carbon monoxide bubbled for 2 min resulted in
the loss of 81% of the original activity. SKF 525-A seems to be a
better inhibitor of the 10-hydroxylase than is metyrapone. SKF 525-A
at a concentration of 0.2 mM inhibited the reaction to the extent of
77% whereas metyrapone inhibited to nearly the same extent (74%,
Table 1) at a concentration of 1.0 mM. Both cytochrome c and
piperinyl butoxide inhibited the hydroxylase activity 86 and 57%,
respectively (Table 1).
Binding Studies. Compound I elicited type I binding spectrum
(lmax 385–388 nm, lmin 420–423 nm) with control and PB-induced
microsomes whereas with 3-MC-induced microsomes it produced a
reverse type I difference spectrum (lmax 420–425 nm, lmin 385–390
nm). The value of spectral dissociation constant (Ks) calculated from
the double reciprocal plot (as mentioned under Materials and Meth-
ods) for this compound with control and PB-induced microsomes was
62.5 and 38.5 mM, respectively. The binding affinity of compound I
toward PB-induced microsomes is comparatively higher than with
control microsomes.
Effect of Compound I, R-(1)-Pulegone, and Carbon Tetrachlo-
ride on Hepatic Microsomal Enzymes. A number of liver microso-
mal enzymes and SGPT levels were studied 24 h after the i.p.
administration of 5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone (I)
to rats. The effects of compound I on the hepatic microsomal enzymes
were compared with the effects observed after a single dose of i.p.
administration of known hepatotoxins viz. R-(1)-pulegone (250 mg/kg
of b.wt.) and CCl4 (0.6 ml/kg of b.wt.) to rats. The results are summarized
in Table 3. These studies were carried out 24 h after the treatment with
test compounds.
Consistent with the earlier reports (Boyd et al., 1980; Mannering et
al., 1981; Plaa, 1981; Gordon et al., 1982; Moorthy et al., 1989b,
1991), it was observed that i.p. administration of a single dose of
R-(1)-pulegone or CCl4 to rats caused marked decrease in microso-
mal cytochrome P-450, aminopyrine N-demethylase, and glucose-6-
phosphatase activities (Table 3). During this period, a significant
increase in SGPT level was also observed (Table 3). The effects of i.p.
administration of a single dose of compound I resulted in 26, 23, and
41% decrease in cytochrome P-450, glucose-6-phosphatase, and
aminopyrine N-demethylase activities, respectively, after 24 h of
administration (Table 3). An 11-fold increase in SGPT level was also
observed (Table 3). However, the decrease in the level of cytochrome
P-450 and glucose-6-phosphatase and increase in SGPT value after
the administration of test compounds were considerably more in the
case of R-(1)-pulegone and CCl4 than with compound I (Table 3),
whereas aminopyrine N-demethylase was affected to the same extent
with all the compounds tested during this period (Table 3). There was
FIG. 4. PMR spectra and electron impact mass spectra (inset) of 5,5-dimethyl-2-(1-hydroxy methylethyl)-cyclohexanone (IX).
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no significant change in the level of cytochrome b5 after the admin-
istration of compound I (data not shown).
Pretreatment Studies. Pretreatment of rats with PB for 4 days
before i.p. administration (250 mg/kg of b.wt.) of compound I poten-
tiated the hepatotoxicity caused by I (Table 4). Compound I caused
58, 49, and 48% decrease in the levels of cytochrome P-450, glucose-
6-phosphatase, and aminopyrine N-demethylase in PB-treated rats as
against 26, 23, and 40% in untreated rats, respectively (Table 4). It
was also noticed that SGPT was 23-fold higher than the control when
compound I was administered to PB-treated rats. Contrary to these
observations, pretreatments of rats with 3-MC resulted in complete
protection from the toxicity mediated by compound I. Administration
of compound I to 3-MC pretreated rats did not alter significantly
cytochrome P-450, glucose-6-phosphatase, and aminopyrine N-de-
methylase (Table 4). There was not any noticeable change in the level
of SGPT as compared with that of rats treated with 3-MC alone (Table
4).
Discussion
The purpose of this study was to probe further the significance of
a chiral center at C-5 in R-(1)-pulegone-mediated toxicity. To eval-
uate this aspect, 5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone
(I) was chosen as the test compound because it is structurally similar
to the potent hepatotoxin, R-(1)-pulegone except that the C-5 hydro-
gen in pulegone is substituted by a methyl group with the result that
it has lost its chirality. This structural modification has blocked one of
the major metabolic pathways of R-(1)-pulegone initiated through
hydroxylation at the C-5 position (Madyastha and Raj, 1993).
This study represents the characterization of various metabolites
isolated from the urine of the rats dosed with I. The identification of
these metabolites has provided not only a basis for understanding the
significance of two major pathways, viz. C-5 and C-9 hydroxylation
pathways involved in the metabolism of pulegone, but also indicated
the possible mode of metabolism if the C-5 hydroxylation pathway is
blocked through structural modification. It can be inferred from this
study that compound I is essentially metabolized following a major
pathway A (Fig. 1). However, the proposed pathway is speculative,
but it is supported by in vitro study, precedence from the early work
on metabolism of R-(1)-pulegone, and chemical logic. As expected,
the major pathway is initiated through the regiospecific oxidation of
the methyl group syn to the carbonyl group resulting in the formation
of v-hydroxylated derivative (II, Fig. 1). It is interesting to note that
most of the metabolites (75–80% of the total metabolites formed)
isolated appear to have been derived from a common intermediate,
viz. 10-hydroxy compound (II, Fig. 1). The metabolite II readily
undergoes intramolecular cyclization followed by dehydration to yield
a furanoterpene (III, Fig. 1) in a manner analogous to the formation of
R-(1)-menthofuran (Gordon et al., 1987; Madyastha and Raj, 1990),
S-(2)-menthofuran (Madyastha and Gaikwad, 1998) and 6,7-dehy-
dromenthofuran (Madyastha and Gaikwad, 1999) from R-(1)-pule-
gone, S-(2)-pulegone, and piperitenone, respectively. In support of
this pathway, it was demonstrated that PB-induced rat liver micro-
somes convert I to a furanoterpene (III, Fig. 1) in the presence of
NADPH and air, presumably through the intermediacy of II (Fig. 1).
It was also noticed that the transformation of I to III was significantly
higher with PB-induced than control microsomes. Formation of
furanoterpene (III) from I was inhibited to a significant extent by
reagents, which are recognized inhibitors of the reactions mediated by
the cytochrome P-450 system (Table 1). All these observations clearly
suggest that the major pathway A (Fig. 1) initiated through regiospe-
cific hydroxylation of I is catalyzed by the liver microsomal cyto-
chrome P-450 system. In support of this assumption, it was demon-
FIG. 5. PMR spectra and electron impact mass spectra (inset) of 3-hydroxy-5-hydroxymethyl-5-methyl-2-(1-methylethylidene)-cyclohexanone (XI).
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strated earlier that the microsomal cytochrome P-450 system carries
out the regiospecific oxidation of R-(1)-pulegone to its allylic alcohol
(9-hydroxypulegone) where the hydroxyl and the keto groups are syn
to each other. The allylic alcohol readily undergoes intramolecular
cyclization followed by dehydration to menthofuran, a furanoterpene
(Gordon et al., 1987; McClanahan et al., 1989; Madyastha and Raj,
1990). A similar sequence of reactions has also been shown to be
involved in the transformation of piperitenone to 6,7-dehydromentho-
furan (Madyastha and Gaikwad, 1999). In this study it is reasonable to
assume that the allylic alcohol (II, Fig. 1) formed from I gets con-
verted to a furanoterpene (III, Fig. 1) in a manner analogous to the
formation of menthofuran and 6,7-dehydromenthofuran from R-(1)-
pulegone and piperitenone, respectively. However, II could not be
isolated from both in vivo and in vitro experiments because it readily
undergoes intramolecular cyclization to a hemiketal. A similar obser-
vation was made earlier during the enzymatic conversion of R-(1)-
FIG. 6. PMR spectra and electron impact mass spectra (inset) of 5,6-dihydro-3,6,6-trimethyl-2(4H)-benzofuranone (VIII).
FIG. 7. 13C NMR spectra of 5,6-dihydro-3,6,6-trimethyl-2(4H)-benzofuranone (VIII).
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pulegone to menthofuran via the intermediacy of 9-hydroxy pulegone
(Gordon et al., 1987; Madyastha and Raj, 1990). When the exocyclic
double bond in II is reduced as in IX (Fig. 1), the compound does not
get cyclized, hence we could isolate IX from the urine extract as a
minor metabolite possibly derived from II.
It is quite possible that the furanoterpene (III) formed could be
transformed into an hydroxylactone (VII), which can either dehydrate
to produce an unsaturated lactone (VIII, Fig. 1) or opening of the
hydroxylactone (VII) as shown in Fig. 1 followed by allylic hydroxy-
lation could yield the metabolite XIII (Fig. 1). The first step in this
sequence of reactions (III 3 VII, Fig. 1) could be nonenzymatic. In
support of this proposed catabolic sequence (Fig. 1), it has been
reported earlier that lower furanoterpenes (Kubota, 1969) and fura-
noeremophilanes (Pinder, 1977) easily get transformed into their
corresponding hydroxylactone or unsaturated lactones either in the
presence of a mild oxidizing agent or by auto-oxidation. This facile
transformation is normally used in structure determination of furanot-
erpenes (Novotny and So¨rm, 1965). It appears that the furanoterpene
III is the major metabolite of I although a significant portion of it gets
further transformed to metabolites VIII and XIII (Fig. 1). In fact,
metabolites III, VIII, and XIII together constitute nearly 67% of the
total metabolites formed (Table 2).
Studies carried out earlier both in vivo and in vitro have demon-
strated that R-(1)-pulegone, S-(2)-pulegone, and menthofuran get
converted to an a, b-unsaturated-g-ketoaldehyde (McClanahan et al.,
1989; Madyastha and Raj, 1990, 1992; Madyastha and Gaikwad,
1998). These studies have indicated the possible involvement of liver
microsomal cytochrome P-450 in this transformation and the conver-
FIG. 8. PMR spectra and electron impact mass spectra (inset) of 5,5-dimethyl-3-hydroxy-2-(1-carboxyethylidene)-cyclohexanone (XIII).
TABLE 3
Effect of i.p. administration of a single dose of 5,5-dimethyl-2-(1-methylethylidene)-cyclohexanone (I, 250 mg/kg), R-(1)-pulegone (250 mg/kg), and CCl4 (0.6 ml/kg)
on rat liver microsomal enzymes and SGPT 24 h after the treatment
Enzyme Activity Controla
Test Compounds
Compound I Percentage of change
over control R-(1)-pulegone
Percentage of change
over control CCl4
Percentage of change
over control
Cytochrome P-450
(nmol/ mg of
protein)
0.50 6 0.01 0.37 6 0.02 25.80 (2) 0.28 6 0.06 44.00 (2) 0.205 6 0.05 59.00 (2)
Glucose 6-
phosphatase
(nmol pi/min/
mg of protein)
226.90 6 20.6 174.00 6 11.25 23.30 (2) 131.25 6 22.5 42.20 (2) 133.10 6 1.9 41.00 (2)
Aminopyrine N-
demethylase
(nmol HCHO/
min/mg of
protein)
6.40 6 0.9 3.80 6 0.2 40.60 (2) 3.75 6 0.5 41.00 (2) 3.90 6 0.3 39.00 (2)
SGPT (U/ml) 31.15 6 3.15 378.70 6 1.4 11.20† (1) 639.50 6 4.5 19.50† (1) 488.00 6 7 14.70†(1)
a Animals treated with vehicle alone. Animals were sacrificed 24 h after the administration of test compounds. Values represent mean 6 S.D. of three independent experiments consisting of tissues
pooled from six rats. (2) indicates percent decrease over control and (1) indicates percent increase over control.
†
, Values represent number of fold change over control. Other details of the experiment are as mentioned in Materials and Methods.
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sion is possibly through the intermediacy of an epoxide. So it is quite
possible that the transformation of III to IV (Fig. 1) may take place in
a manner analogous to the formation of a, b-unsaturated-g-ketoalde-
hyde from R-(1)-pulegone and menthofuran. Additional metabolism
of this unsaturated ketoaldehyde results in the formation of 4-methyl-
2-cyclohexenone, which also gets transformed to p-cresol, one of the
major toxic metabolites of pulegone and menthofuran (Madyastha and
Raj, 1991, 1992, 1993; Madyastha and Gaikwad, 1998). The sequence
of reactions involved in this transformation appears to be reductive
elimination of the keto group in a, b-unsaturated-g-ketoaldehyde and
hydration of the exocyclic double bond followed by a retro-aldol type
reaction, which could easily yield 4-methyl-2-cyclohexanone. In this
investigation, it has been noticed that the metabolism of compound I
does not yield p-cresol as one of the metabolites, suggesting that the
a, b-unsaturated-g-ketoaldehyde (IV, Fig. 1) is not subjected to the
above sequence of reactions. However, this study has demonstrated
that 3,3-dimethylcyclohexanone (VI, Fig. 1) is one of the minor
metabolites of I. This minor metabolite (VI) could have been formed
as a consequence of nonenzymatic cleavage of the exocyclic double
bond in IV followed by reduction as shown in the Fig. 1. Similar
nonenzymatic cleavage has been proposed earlier for the formation of
5-methyl-2-cyclohexenone and 3-methylcyclohexanone from an a,
b-unsaturated-g-ketoaldehyde derived from menthofuran (Madyastha
and Raj, 1992).
The minor pathway B (Fig. 1) is involved in the formation of
metabolites X and XI. These minor metabolites could have been
formed through allylic hydroxylation of I followed by methyl oxida-
tion. It is quite possible that metabolites formed via the major pathway
(A, Fig. 1) may be mostly responsible for the observed toxicity
mediated by I. The major metabolites formed along this pathway are
furanoterpene (III) and a lactone (VIII). In fact, menthofuran, which
is structurally very similar to metabolite III, is a potent hepatotoxin
(Madyastha and Raj, 1994). Many sesquiterpene lactones with an a,
b-unsaturated-g-lactone structural unit as seen in metabolite VIII,
have been shown to possess significant antitumor and cytotoxic ac-
tivities (Rodriguez et al., 1976).
In this study we have compared the hepatotoxic potential of com-
pound I with known hepatotoxins such as R-(1)-pulegone and CCl4.
It is to be noted that one cannot draw any real conclusion from the
relative toxicity studies without obtaining kinetic data for the metab-
olism of R-(1)-pulegone and its analog (I). However, these are
preliminary studies that point out that compound I is significantly less
hepatotoxic than R-(1)-pulegone and CCl4. This study has demon-
strated that compound I causes considerable hepatotoxicity in rats as
evidenced by a 11-fold increase in SGPT level and a 23% loss of
glucose-6-phosphatase 24 h after a single dose of I (Table 3). In
addition, decrease in cytochrome P-450 as well as aminopyrine N-
demethylase was also observed (Table 3), indicating that compound I
interferes with cytochrome P-450-mediated metabolism possibly
through its destruction. Increased levels of SGPT as well as glucose-
6-phosphatase indicate possible hepatic injury caused by compound I.
Earlier it was reported that rats treated with hepatotoxic agents such as
CCl4 showed elevated SGPT levels as well as extensive centrilobular
necrosis (Balazs et al., 1961). However, the increased levels of SGPT
as well as decreased levels of glucose-6-phosphatase observed in the
case of compound I are significantly lower than these values obtained
from rats treated with hepatotoxic agents such as R-(1)-pulegone or
CCl4 (Table 3). This suggests that compound I is not as potent a
hepatotoxin as R-(1)-pulegone or CCl4. It appears that substitution of
C-5 hydrogen in R-(1)-pulegone with a methyl group considerably
decreases its hepatotoxic potential. This could possibly be due to the
fact that in such a compound, C-5 hydroxylation is not possible. As a
consequence of this, compound I is predominantly metabolized fol-
lowing a pathway initiated through regiospecific hydroxylation of a
methyl syn to the carbonyl, resulting in the formation of a furanoter-
pene (III) as shown in Fig. 1. In fact, most of the metabolites isolated
and characterized in this study appear to have been derived from this
metabolite (III). Our studies point out that metabolites derived through
the C-5 hydroxylation pathway involved in the biotransformation of
R-(1)-pulegone play a considerable role in eliciting R-(1)-pulegone-
mediated toxicity.
Pretreatment of rats with PB, a known inducer of cytochrome
P-450, before administration of I, resulted in potentiation of hepato-
toxicity as evidenced by a significant increase in SGPT levels,
whereas pretreatment with 3-MC protected from it (Table 4). It
appears that PB-induced cytochrome P-450-catalyzed reactive metab-
olite(s) may be responsible for the toxicity caused by compound I. Our
results also suggest that the hepatotoxic potential of R-(1)-pulegone
can be reduced considerably if the C-5 hydroxylation pathway in-
volved in its metabolism is blocked through structural modification. It
appears that the C-5 chiral center contributes substantially to R-(1)-
pulegone-mediated toxicity.
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